S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

Cytek BioSciences Stock Forecast, Price & News

-1.02 (-5.06%)
(As of 12/1/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
163,522 shs
Average Volume
265,303 shs
Market Capitalization
$2.56 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CTKB News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Cytek BioSciences logo

About Cytek BioSciences

Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif.


See More Headlines

Industry, Sector and Symbol

Analytical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Free Float
Market Cap
$2.56 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.63 out of 5 stars

Medical Sector

989th out of 1,392 stocks

Analytical Instruments Industry

25th out of 33 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Cytek BioSciences (NASDAQ:CTKB) Frequently Asked Questions

Is Cytek BioSciences a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytek BioSciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cytek BioSciences stock.
View analyst ratings for Cytek BioSciences
or view top-rated stocks.

When is Cytek BioSciences' next earnings date?

Cytek BioSciences is scheduled to release its next quarterly earnings announcement on Monday, February 14th 2022.
View our earnings forecast for Cytek BioSciences

How were Cytek BioSciences' earnings last quarter?

Cytek BioSciences, Inc. (NASDAQ:CTKB) announced its quarterly earnings data on Monday, November, 8th. The company reported $0.02 EPS for the quarter, meeting the consensus estimate of $0.02. The company had revenue of $34.38 million for the quarter.
View Cytek BioSciences' earnings history

What price target have analysts set for CTKB?

4 brokers have issued 12 month price targets for Cytek BioSciences' shares. Their forecasts range from $26.00 to $28.00. On average, they anticipate Cytek BioSciences' share price to reach $27.33 in the next year. This suggests a possible upside of 42.7% from the stock's current price.
View analysts' price targets for Cytek BioSciences
or view top-rated stocks among Wall Street analysts.

When did Cytek BioSciences IPO?

(CTKB) raised $248 million in an IPO on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share.

What is Cytek BioSciences' stock symbol?

Cytek BioSciences trades on the NASDAQ under the ticker symbol "CTKB."

When does Cytek BioSciences' lock-up period expire?

Cytek BioSciences' lock-up period expires on Wednesday, January 19th. Cytek BioSciences had issued 14,564,635 shares in its public offering on July 23rd. The total size of the offering was $247,598,795 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.

Who are Cytek BioSciences' major shareholders?

Cytek BioSciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (7.19%), FIL Ltd (1.99%), BlackRock Inc. (1.39%), Pura Vida Investments LLC (0.33%), Sectoral Asset Management Inc (0.25%) and Geode Capital Management LLC (0.24%).

Which major investors are buying Cytek BioSciences stock?

CTKB stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., FIL Ltd, BlackRock Inc., Pura Vida Investments LLC, Sectoral Asset Management Inc, Geode Capital Management LLC, Millennium Management LLC, and Caas Capital Management LP.

How do I buy shares of Cytek BioSciences?

Shares of CTKB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytek BioSciences' stock price today?

One share of CTKB stock can currently be purchased for approximately $19.15.

How much money does Cytek BioSciences make?

Cytek BioSciences has a market capitalization of $2.56 billion.

How many employees does Cytek BioSciences have?

Cytek BioSciences employs 2,021 workers across the globe.

What is Cytek BioSciences' official website?

The official website for Cytek BioSciences is www.cytekdev.com.

How can I contact Cytek BioSciences?

The company can be reached via phone at 877-922-9835 or via email at [email protected].

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.